8月14日 - ** Sarepta Therapeutics SRPT.O股价盘前上涨3%至21美元
** 与 Arrowhead Pharmaceuticals ARWR.O 合作开发的实验性基因药物SRP-1003 在早中期研究中取得进展 - SRPT
** 试验里程碑的完成触发了向ARWR支付1亿美元；SRPT出售1.74亿美元的ARWR普通股以换取现金
** SRP-1003靶向肌肉衰弱性疾病肌营养不良症、面肱肌营养不良症
** SRPT 预计将于今年下半年获得研究的早期数据
** 另外，执行副总裁兼首席技术运营官比拉尔-阿里夫（Bilal Arif）将于 9 月 16 日因重组离职
** 截至上一交易日收盘，SRPT股价下跌近83%，而纳斯达克生物技术指数.NBI上涨7.75% 。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.